Flunarizine Versus Topiramate for Chronic Migraine Prophylaxis

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Chronic migraine (CM) is a prevalent and devastating disorder with limited therapeutic options. This study explored the efficacy of 10 mg/day flunarizine for CM prophylaxis as compared with 50 mg/day topiramate.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taipei Veterans General Hospital, Taiwan
• Treatments: Flunarizine; Topiramate

Criteria

Inclusion Criteria:

• ICHD-IIR criteria for CM (as reported by the patient)

• Experienced ≥7 days of headache lasting ≥30 min during T0 (-2 week to 0 week).

• On ≥4 of these days, subjects were required to have experienced migrainous headache

• Prophylaxis-naïve (i.e., patients could not receive any preventive medications)

• With and without medication overuse

Exclusion Criteria:

• Headache type other than CM

• Migraine onset after the age of 50 years

• CM onset after the age of 60 years

• Previous history of migraine prophylaxis before enrollment

• Pregnancy or nursing status

• History of hepatic or renal disorder, nephrolithiasis or other severe systemic disease

• Severe depression (BDI score ≥ 30 at visit 1)

• Conditions incompatible with MRI, such as claustrophobia or metallic or electric implants